| Expanded Learning Session #1 |
Immunotherapy will only be curative if delivered with RT |
| Expanded Learning Session #2 |
Biologic/genetic markers are the only method to select patients for combined RT and immunotherapy |
| Expanded Learning Session #3 |
Imaging at the micrometer scale is possible and required for RT to cure metastatic disease |
| Expanded Learning Session #4 |
Treating the primary site is necessary in curing metastatic Disease |
| Expanded Learning Session #5 |
Radiopharmaceuticals will replace external beam RT for treament of metastasis in the next decade |
| Expanded Learning Session #6 |
Artificial intelligence will drive who we treat for cure with metastatic disease and how we treat them |
| Expanded Learning Session #7 |
Treatment of oligometastatic disease with RT will allow survival to soar in low income nations |
| Expanded Learning Session #8 |
RT is redefining the cure of metastatic breast cancer |
| Expanded Learning Session #9 |
RT is becoming the standard for curing oligometastatic lung cancer |
| Expanded Learning Session #10 |
RT for metastatic GI cancer improves patient prognosis |
| Expanded Learning Session #11 |
RT for oligometastatic prostate cancer will replace systemic therapy |
| Expanded Learning Session #12 |
We have not maximized the radiotherapeutic potential for curing brain metastases |
| Expanded Learning Session #13 |
When chemotherapy fails to cure, RT can change the outcome with/without immunomodulation in hematologic malignancies |